The brain-penetrant ALK inhibitor lorlatinib is effective in first line treatment of ALK-rearranged non-small-cell lung cancer (NSCLC), an Australian-led phase 3 trial has shown. An interim analysis of the CROWN trial, presented at ESMO Virtual Congress 2020 by Professor Ben Solomon, medical oncologist at the Peter MacCallum Cancer Centre, Melbourne, showed that lorlatinib significantly improved ...
Prof Ben Solomon: ALK inhibitor effective in first line therapy for NSCLC
By Michael Woodhead
22 Sep 2020